CRISPR Therapeutics AG Book Value 2011-2026 | CRSP

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value CRISPR Therapeutics AG

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.92 B	1.93 B	1.88 B	1.88 B	2.4 B	1.66 B	939 M	392 M	188 M	233 M	-29.1 M	-6.97 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.4 B	-29.1 M	1.12 B

Quarterly Book Value CRISPR Therapeutics AG

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
1.92 B	1.71 B	1.83 B	1.93 B	1.94 B	1.98 B	2.08 B	1.88 B	1.73 B	1.82 B	1.85 B	1.88 B	1.95 B	2.09 B	2.24 B	2.4 B	2.51 B	2.6 B	1.81 B	1.66 B	1.66 B	1.66 B	1.66 B	939 M	939 M	939 M	939 M	392 M	392 M	392 M	392 M	188 M	188 M	188 M	188 M	233 M	233 M	233 M	233 M	35.4 M	35.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.6 B	35.4 M	1.27 B

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Autolus Therapeutics plc AUTL	427 M	$ 1.68	2.44 %	$ 429 M	Britain
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Kamada Ltd. KMDA	319 M	$ 8.81	1.73 %	$ 260 M	Israel
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Adagene ADAG	50.5 M	$ 3.26	0.62 %	$ 183 M	China
Alterity Therapeutics Limited ATHE	35.5 M	$ 3.28	-2.62 %	$ 7.89 B	Australia
Evogene Ltd. EVGN	14.8 M	$ 0.81	-9.28 %	$ 27.9 M	Israel
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Akouos AKUS	234 M	-	0.23 %	$ 488 M	USA
Nymox Pharmaceutical Corporation NYMX	-6.78 M	-	-19.68 %	$ 18.4 M	Canada
Albireo Pharma ALBO	176 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	11.8 M	$ 0.79	-1.29 %	$ 4.31 M	China
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
AlloVir ALVR	113 M	-	4.14 %	$ 49.1 M	USA
XTL Biopharmaceuticals Ltd. XTLB	2.71 M	$ 0.88	-1.43 %	$ 442 M	Israel
Allena Pharmaceuticals ALNA	18.9 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	3.36 M	-	-11.43 %	$ 502 K	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	60.8 M	-	-	$ 10.1 M	USA
Aptose Biosciences APTO	-4.54 M	-	-45.71 %	$ 1.2 M	Canada
Aravive ARAV	10.7 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Ascendis Pharma A/S ASND	-163 M	$ 224.42	-2.52 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Arena Pharmaceuticals ARNA	785 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	60.2 M	-	3.77 %	$ 22.4 M	USA
AVROBIO AVRO	94.7 M	-	1083.1 %	$ 745 M	USA
Anavex Life Sciences Corp. AVXL	94.9 M	$ 4.13	0.12 %	$ 352 M	USA
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	124 M	$ 2.36	2.27 %	$ 14.8 M	USA
Aptinyx APTX	38.3 M	-	-39.0 %	$ 4.57 M	USA
AstraZeneca PLC AZN	40.9 B	-	-	$ 96.9 B	Britain
Aridis Pharmaceuticals ARDS	-24.2 M	-	17.91 %	$ 11.1 M	USA
Brickell Biotech BBI	11.6 M	-	-5.38 %	$ 6.06 M	USA
Codexis CDXS	66.9 M	$ 1.17	-0.85 %	$ 85.9 M	USA
Athira Pharma ATHA	44.8 M	-	-	$ 269 M	USA
BioNTech SE BNTX	19.4 B	$ 110.12	-0.28 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	3.5 B	$ 14.49	-0.75 %	$ 4.48 B	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany